LONDON - Antisoma plc has sold its oral fludarabine product to Sanofi-Aventis SA for an immediate cash payment of £39.4 million (US$60 million) and further payments totaling $5 million, in a deal that will extend its cash resources from mid-2010 to 2011, providing sufficient funding to see the two lead therapies through to the end of Phase III. (BioWorld International)